How I Treat ALL: Do All Adults with Ph+ ALL Still Require Allogeneic Transplant?
Wendy Stock, MD, The University of Chicago
Friday, September 8, 2017 5:00 p.m.
Fairmont Chicago, Millennium Park, Chicago, IL
Survival rates for patients with Ph+ ALL have improved significantly in the last decade with the introduction of abl-kinase (TKI) inhibitors to frontline therapy. A variety of regimens incorporating TKI and chemotherapy combinations have emerged and have resulted in high molecular remission rates. Given these high molecular remission rates, there is emerging controversy about the requirement of hematopoietic cell transplantation for long-term survival. Dr. Stock will evaluate both transplant and non-transplant approaches that have been studied in prospective clinical trials and discuss new approaches for targeted treatment for Ph+ ALL.
About the Speaker
Wendy Stock, MD, is a co-leader of The University of Chicago Cancer Research Center’s Program in Hematopoiesis and Hematological Malignancies and is a core member of the Leukemia and Leukemia Correlative Sciences committees in the Alliance, an NCI-sponsored clinical trials cooperative group. She is co-chair of the NCI National Clinical Trials Network (NCTN) Leukemia Steering Committee. She is an authority in treating patients with all types of leukemia and myelodysplastic syndromes, including hematopoietic cell transplants. Her research efforts are directed to the design of clinical trials that tailor therapy to the individual patient.
back to top